Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment

Gut

Volumn 63, Issue 4, 2014, Pages 567-577

  Tillack, Cornelia ^a   Ehmann, Laura Maximiliane ^b   Friedrich, Matthias ^a,b   Laubender, Rüdiger P ^b   Papay, Pavol ^c   Vogelsang, Harald ^c   Stallhofer, Johannes ^a   Beigel, Florian ^a   Bedynek, Andrea ^b   Wetzke, Martin ^a,d   Maier, Harald ^c   Koburger, Maria ^a   Wagner, Johanna ^a,b   Glas, Jürgen ^a,b,e   Diegelmann, Julia ^a,b   Koglin, Sarah ^b   Dombrowski, Yvonne ^b,f   Schauber, Jürgen ^b   Wollenberg, Andreas ^b   Brand, Stephan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e RWTH AACHEN UNIVERSITY   (Germany)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIPSORIASIS AGENT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; TUMOR NECROSIS FACTOR ANTIBODY; USTEKINUMAB;

ADULT; ALOPECIA; ARTICLE; BODY MASS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG INDICATION; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GUTTATE PSORIASIS; HUMAN; IL12B GENE; IL23A GENE; IL23R GENNE; IMMUNOHISTOCHEMISTRY; INCIDENCE; INFLAMMATORY BOWEL DISEASE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PSORIASIS; PUSTULAR PSORIASIS; PUSTULOSIS PALMOPLANTARIS; SCREENING; SKIN BIOPSY; SMOKING; TH1 CELL; TH17 CELL; TREATMENT RESPONSE; ULCERATIVE COLITIS;

CROHN'S DISEASE; IBD; T LYMPHOCYTES; TNF-ALPHA; ULCERATIVE COLITIS;

ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKINS; MALE; PROSPECTIVE STUDIES; PSORIASIS; SKIN; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84895424744     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302853     Document Type: Article

References (67)

1. Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012;18:201-11.
2. Beigel F, Jurgens M, Filik L, et al. Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease. Inflamm Bowel Dis 2009;15:1240-4.
3. Beigel F, Jurgens M, Tillack C, et al. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. Nat Rev Gastroenterol Hepatol 2009;6:433-6.
4. Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010;8:1048-55.
5. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009;20:100-8.
6. Cullen G, Kroshinsky D, Cheifetz AS, et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011;34:1318-27.
7. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009;58:1152-67.
8. Brand S, Beigel F, Olszak T, et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006;290:G827-38.
9. Schmechel S, Konrad A, Diegelmann J, et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis 2008;14:204-12. (Pubitemid 351288041)
10. Dambacher J, Beigel F, Zitzmann K, et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 2009;58:1207-17.
11. Seiderer J, Elben I, Diegelmann J, et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p. His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008;14:437-45. (Pubitemid 351571823)
12. Kryczek I, Bruce AT, Gudjonsson JE, et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 2008;181:4733-41.
13. Ma HL, Liang S, Li J, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008;118:597-607. (Pubitemid 351206549)
14. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006;36:1309-23.
15. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-3. (Pubitemid 44871953)
16. Glas J, Seiderer J, Wetzke M, et al. rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS ONE 2007;2:e819.
17. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273-90. (Pubitemid 46175676)
18. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-25.
19. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246-52.
20. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-79. (Pubitemid 39482500)
21. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135:1130-41.
22. Sandborn WJ, Gasink C, Gao LL, et al. A multicenter, randomized, double-blind, placebo-controlled phase2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severely active Crohn's disease: results through week 22 from the Certifi trial. Gastroenterology 2011;140;S-109.
23. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012;367:1519-28.
24. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6; discussion 16-9. (Pubitemid 20015811)
25. Glas J, Seiderer J, Wagner J, et al. Analysis of IL12B gene variants in inflammatory bowel disease. PLoS ONE 2012;7:e34349.
26. Glas J, Seiderer J, Tillack C, et al. The NOD2 single nucleotide polymorphisms rs2066843 and rs2076756 are novel and common Crohn's disease susceptibility gene variants. PLoS ONE 2010;5:e14466.
27. Glas J, Seiderer J, Fries C, et al. CEACAM6 gene variants in inflammatory bowel disease. PLoS ONE 2011;6:e19319.
28. Glas J, Stallhofer J, Ripke S, et al. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am J Gastroenterol 2009;104:1737-44.
29. Seneschal J, Milpied B, Vergier B, et al. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 2009;161:1081-8.
30. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74. (Pubitemid 351671883)
31. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84. (Pubitemid 351671884)
32. Griffiths CE, Strober BE, Van De Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28.
33. Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009;41:199-204.
34. Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008;4:e1000041.
35. Zhang XJ, Huang W, Yang S, et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 2009;41:205-10.
36. Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc Natl Acad Sci USA 2011;108:9560-5.
37. Di Meglio P, Di Cesare A, Laggner U, et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS ONE 2011;6:e17160.
38. Pidasheva S, Trifari S, Phillips A, et al. Functional studies on the IBD susceptibility gene IL23R implicate reduced receptor function in the protective genetic variant R381Q. PLoS ONE 2011;6:e25038.
39. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203:2271-9. (Pubitemid 44498362)
40. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509.
41. Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-76.
42. Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007;156:486-91.
43. Shmidt E, Wetter DA, Ferguson SB, et al. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 2012;67:e179-85.
44. Iborra M, Beltran B, Bastida G, et al. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. J Crohns Colitis 2011;5:157-61.
45. Guerra I, Algaba A, Perez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis 2012;6:518-23.
46. Buisson A, Cuny JF, Barbaud A, et al. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:1175-80.
47. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol 2012;9:496-503.
48. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009;68:209-15.
49. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-7. (Pubitemid 40981424)
50. Manni E, Barachini P. Psoriasis induced by infliximab in a patient suffering from Crohn's disease. Int J Immunopathol Pharmacol 2009;22:841-4.
51. Yu RY, Gallagher G. A naturally occurring, soluble antagonist of human IL-23 inhibits the development and in vitro function of human Th17 cells. J Immunol 2010;185:7302-8.
52. Sherlock ME, Walters T, Tabbers MM, et al. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn's disease and a potential association with IL-23 receptor polymorphisms. J Pediatr Gastroenterol Nutr 2013;56:512-8.
53. Palucka AK, Blanck JP, Bennett L, et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005;102:3372-7. (Pubitemid 40328052)
54. Wollenberg A, Wagner M, Gunther S, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002;119:1096-102. (Pubitemid 35434173)
55. De Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-31. (Pubitemid 46294587)
56. Schroepf S, Kappler R, Brand S, et al. Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis 16:1882-90.
57. Teunissen MB, Koomen CW, De Waal Malefyt R, et al. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111:645-9. (Pubitemid 28452327)
58. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9.
59. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9.
60. Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009;87:523-36.
61. Boniface K, Bernard FX, Garcia M, et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005;174:3695-702. (Pubitemid 40354080)
62. http://www.clinicaltrials.gov/show/NCT00563524 (accessed 1 Oct. 2012).
63. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113:1664-75. (Pubitemid 39071656)
64. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T (H) 17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-51. (Pubitemid 46232884)
65. Downs AM, Dunnill MG. Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin Exp Dermatol 2000;25:351-2. (Pubitemid 30670597)
66. Niess JH, Leithauser F, Adler G, et al. Commensal gut flora drives the expansion of proinflammatory CD4T cells in the colonic lamina propria under normal and inflammatory conditions. J Immunol 2008;180:559-68.
67. Ramgolam VS, Sha Y, Jin J, et al. IFN-beta inhibits human Th17 cell differentiation. J Immunol 2009;183:5418-27.